Bluejay Diagnostics, Inc. (BJDX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Bluejay Diagnostics, Inc. on December 3, 2024. The Company is an emerging growth company incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "BJDX".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory compliance matter regarding stock listing status.
Material Changes
The Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market that it has regained compliance with Nasdaq Listing Rule 5550(a)(2). This compliance was achieved because the closing bid price of the Company's common stock remained at least $1.00 per share for the required period. Consequently, the minimum bid price deficiency previously disclosed on March 4, 2024, is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or discussion of future risks and contingencies beyond the resolution of the specific listing deficiency. No unusual items were reported.
Key Facts for Investor Verification
- Bluejay Diagnostics has resolved its minimum bid price deficiency with Nasdaq.
- The stock price sustained a closing bid of at least $1.00 per share for the required compliance period.
- The deficiency matter originally disclosed on March 4, 2024, is officially closed as of December 3, 2024.
- No financial performance data is included in this specific filing.